Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 39: 1689-1693, 1993;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Krouwer, J. S.
Right arrow Articles by Schlain, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krouwer, J. S.
Right arrow Articles by Schlain, B.

Clinical Chemistry, Vol 39, 1689-1693, Copyright © 1993 by American Association for Clinical Chemistry

A method to quantify deviations from assay linearity [published erratum appears in Clin Chem 1994 Sep;40(9):1781]

JS Krouwer and B Schlain
Ciba Corning Diagnostics Corp., Medfield, MA 02052.

We present a statistical method to quantify deviations from linearity for assays that veer from linear assay responses. Our procedure handles the common case of unequally spaced analyte levels and nonconstant variance and provides a least-squares estimate with a confidence interval for the amount of deviation from assay linearity at a specified analyte concentration. This estimate of assay bias due to nonlinearity goes beyond the NCCLS EP6 lack-of-fit test, which tests for only the presence of nonlinearity. Knowing that nonlinearity is present is insufficient; users need to know the magnitude of the bias caused by nonlinearity. Our method can also be used with multifactor designs that estimate other systematic assay effects such as drift and carryover, thus obviating the need for a separate protocol to assess linearity. The procedure is carried out by adding extra columns to the design matrix corresponding to the concentration level(s) of interest. The extra columns, which replace the quadratic column, are orthogonal to all other columns. We describe a general method of constructing the new columns, and illustrate the procedure with a manual ammonia assay example dataset from EP6.


The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
M. Cronin, C. Sangli, M.-L. Liu, M. Pho, D. Dutta, A. Nguyen, J. Jeong, J. Wu, K. C. Langone, and D. Watson
Analytical Validation of the Oncotype DX Genomic Diagnostic Test for Recurrence Prognosis and Therapeutic Response Prediction in Node-Negative, Estrogen Receptor-Positive Breast Cancer
Clin. Chem., June 1, 2007; 53(6): 1084 - 1091.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1993 by the American Association for Clinical Chemistry.